# Regeneron Pharmaceuticals, Inc. (REGN) — Q3-2022 Earnings Results

**Report date:** 2022-11-03 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q3-2022

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Beats on EPS, Stock Down 0.24%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $11.14 | N/A | +30.31% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Overall, management expressed confidence in their product lineup and future prospects. However, they did not provide specific guidance for the upcoming quarters.

**Key quotes:**

> Management highlighted strong performance in key product areas.

> They noted ongoing investments in research and development.

> There was an emphasis on maintaining a strong pipeline for future growth.

### Guidance Changes

No forward guidance was provided during the earnings call.

### What It Means

Regeneron's strong EPS performance indicates better-than-expected profitability, which is a positive sign for investors. However, the stock's slight decline of 0.24% suggests that investors may have been looking for more detailed guidance or revenue figures. The lack of revenue data and forward guidance could lead to uncertainty in the market moving forward.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q3-2022_